Focusing on Value Creation by Providing Sponsors with Early Stage Development to Full Scale Manufacture: What Does This Mean for Customer?
Changes in the market place has created a situation where the traditional strategies between suppliers and pharma companies has failed to deliver the outcomes and results that the customer demands. Consequently, a new offer approach has been developed by forward looking CMOs, which is the co-creation of value formed through effective strategic partnerships. By focusing on the concept of value, new strategies and solutions have been developed, through close alignment between suppliers and customers, which are proven to ensure that the formulation, development and manufacturing needs of pharmaceutical companies are met in full.
The presenter will draw on his industry experience to provide an example of how a strategic alliance can help form an end to end solution that will reduce the complexity of drug/device development and accelerate the route to market.
Richard Fazackerley, Technical Director, Aesica Pharmaceuticals
Richard Fazackerley has over 27 years’ experience in the Pharmaceutical industry working in senior technical positions for Eisai, Eli Lilly, Roche and Amersham International. With extensive experience in the development, optimisation and commercialisation of Pharmaceutical products he is responsible for leading the technical function and heading up the formulation development services business within Aesica.
Detlef and Richard are both well recognised industry experts and active contributors in various industrial forums, conference and journals.
Who Should Attend?
This webinar will be ideal for academic or pharmaceutical researchers, or professionals in Procurement, Technical, Healthcare and Drug development industries.
Aesica, part of Consort Medical Group is renowned for developing and manufacturing both APIs and finished dose forms to the Pharmaceutical industry. We are constantly developing the technical and analytical skills of our people to ensure that we are capable of meeting the ever-changing demands of our customers.
Our state-of-the-art facilities enable delivery of full API development and manufacturing, formulation development and finished dose manufacturing in a growing number of markets, allowing us to manage our customers supply chain effectively. Most importantly, we are aware that customers want more than a supplier, which is why we work in partnership to provide a flexible, efficient and dependable service.